Axogen agrees to buy nerve-repair device maker BioCircuit for $200 million cash, pricing a $208.7 million stock sale the same morning to fund it

by Maya Okafor · September 10, 2026

Deals & Listings Reporter, The SmallCap Signal

Axogen said Thursday it has signed a definitive agreement to acquire BioCircuit Technologies, a privately held Atlanta medical device company, for $200 million in cash — and, in a release that crossed the wire one minute later, said it had priced a $208.7 million sale of new common stock to pay for it. The two announcements were timestamped 6:00 a.m. and 6:01 a.m. ET. Together they give the peripheral-nerve specialist a commercial device it did not previously own and, at the same time, a materially larger share count.

According to the company's Sept. 10 release, the $200 million is payable in cash at closing, with $1.0 million withheld pending a post-closing purchase price adjustment. The price is subject to customary adjustments for cash, indebtedness, transaction expenses and net working capital. Axogen said it expects the transaction to close in the fourth quarter of 2026, subject to satisfaction of customary closing conditions "including completion of the spin-out of BioCircuit's electronics research and development business" — a carve-out condition that means the business Axogen is buying is not quite the business that exists today. The agreement was announced Thursday; the deal has not closed.

BioCircuit works in peripheral nerve repair and neuromodulation, and the release describes its capabilities as spanning biomaterials, Nitinol precision design and manufacturing, and bioelectronics for nerve stimulation and recording. Its lead product is NerveTape, which the release describes in one place as "the first FDA-cleared sutureless device for repairing transected nerves" and in another as "the first FDA-approved device for sutureless nerve repair." Clearance and approval are different FDA pathways, and the release does not reconcile the two formulations. The stated appeal is procedural: the device lets a surgeon align, connect and protect a severed nerve without placing microsutures, which in principle widens the pool of surgeons and care settings able to attempt the repair.

Axogen's existing franchise is built on nerve grafts, connectors and protective wraps, and the release describes the company as "the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair." Chief Executive Michael Dale said in the release that the acquisition "advances our mission to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care," and that "NerveTape's sutureless approach makes high-quality nerve repair simpler and more accessible for surgeons, and we believe it meaningfully advances our innovation agenda by adding a differentiated technology to simplify one of the most challenging aspects of nerve surgery."

Chief Financial Officer Lindsey Hartley framed the economics in non-GAAP terms. "We believe this transaction represents disciplined capital allocation and adds an attractive growth asset that is expected to be accretive to revenue growth, adjusted EBITDA margin and adjusted earnings per share in the first year following close, while maintaining our focus on cash generation," she said in the release. The qualifying language matters: the accretion Axogen is claiming is to adjusted EBITDA margin and adjusted earnings per share, not to GAAP earnings, and the release does not quantify it. Nor does it disclose BioCircuit's revenue, so no purchase multiple can be derived from the document.

BioCircuit Chief Executive Michelle Jarrard said in the same release that "the combination of our two companies could not be a better outcome for patients and surgeons," adding that "Axogen's commercial reach, reimbursement expertise and surgeon relationships create an ideal platform to expand the impact of NerveTape and bring this technology to more patients." The release names Alsora Capital, GRA Venture Fund and Michael Masters of Masters Capital Management among BioCircuit's investors.

The financing is the other half of the story. In a separate release timestamped 6:01 a.m. ET on Sept. 10, Axogen said it had priced an underwritten public offering of 4,910,000 shares of common stock at $42.50 per share, for gross proceeds of approximately $208.7 million before underwriting discounts and estimated expenses, assuming no exercise of the underwriters' option. The underwriters have a 30-day option to purchase up to 736,500 additional shares at the public offering price. The release states that "the proposed offering is expected to close on September 11, 2026, subject to the satisfaction of customary closing conditions" — that is, on Friday.

On use of proceeds, the pricing release states that Axogen intends to use "substantially all of the net proceeds from the offering to fund the cash consideration payable in connection with its previously announced acquisition of BioCircuit Technologies, Inc.," with any remainder going to general corporate purposes including working capital and capital expenditures. BofA Securities, Jefferies and Wells Fargo Securities acted as lead book-running managers, with Mizuho Securities USA as bookrunner and Lake Street Capital Markets as co-manager. The shares are being sold off an automatic shelf registration statement on Form S-3ASR filed with the SEC on Jan. 21, 2026.

That shelf has now been tapped twice this year. Axogen priced an upsized offering of 4,000,000 shares at $31.00 on Jan. 21, 2026, raising approximately $124 million in gross proceeds, with a 30-day option on a further 600,000 shares; the January release said the company intended to use the proceeds for early payoff and termination of its term loan facility with Oberland Capital, working capital, capital expenditures and other general corporate purposes. Taken together, and before any option exercise, the two 2026 offerings represent 8.91 million newly issued shares. Existing holders are diluted accordingly, and the second raise came at a price roughly 37 percent above the first.

For scale, Axogen reported second-quarter 2026 revenue of $69.7 million on July 29, up 23.1 percent year over year, with gross margin of 72.7 percent, down from 74.2 percent a year earlier. On a GAAP basis it posted a net loss of $1.5 million, or $0.03 per share, against net income of $0.6 million, or $0.01 per share, in the year-earlier quarter; on a non-GAAP basis it reported adjusted EBITDA of $8.4 million, down from $9.3 million. It ended the quarter with $94.6 million in cash and cash equivalents and no long-term debt, having eliminated the $48.4 million outstanding at Dec. 31, 2025. The $200 million cash price is more than double the cash the company held at June 30, and the two releases crossed the wire a minute apart.

Axogen's existing outlook, as stated in the July 29 release, is that "for 2026, we expect full-year revenue growth to be at least 24%, or revenue of at least $279 million, gross margin to be at least 73%, and positive free cash flow for the full-year." Thursday's releases did not revise those figures. The acquisition release says Axogen expects the deal "to be accretive to revenue growth, adjusted EBITDA margin and adjusted earnings per share in the first year following close, while maintaining positive free cash flow," and that the company "will provide updated full-year 2026 guidance, including the impact of BioCircuit, following the closing of the transaction."

Several things remain unresolved on the documents as filed. The transaction is conditioned on BioCircuit completing the spin-out of its electronics R&D business, a step outside Axogen's control. No revenue, margin or milestone detail for NerveTape is disclosed, so the accretion claim cannot be independently checked from the release. And the offering closing on Sept. 11 is itself subject to customary conditions; the acquisition financing is not committed capital until it settles. What the documents put on the record is immediate, quantified dilution set against unquantified, management-projected accretion on adjusted measures beginning a year after a close that has not yet happened.